Showing results (311-320 of 344) with videos related to
Sort By:
Pageof 35
International Journal of Hematology|September 19, 2020
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patientsNaoki Takezako, Hiroshi Kosugi, Morio Matsumoto, et al.Annals of Hematology|March 2, 2023
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDAKenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, et al.Blood|March 1, 2024
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasoneYasunori Kogure, Hiroshi Handa, Yuta Ito, et al.British Journal of Haematology|June 26, 2020
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 13, 2016
Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)Daisuke Ogiya, Hirohiko Shibayama, Eiji Nakatani, et al.Journal of Gastroenterology|October 22, 2025
Clinical features and endoscopic polyp management of Peutz-Jeghers syndrome: the 2nd nationwide epidemiological survey in JapanShoko Miyahara, Tomonori Yano, Yoshiko Nakayama, et al.Cell Reports. Medicine|August 30, 2025
Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapyKentaro Hirade, Noritaka Tanaka, Taisuke Kajino, et al.Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.Pageof 35